Back to Search
Start Over
Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
- Source :
- Obstetrics & Gynecology Science, Vol 62, Iss 4, Pp 285-289 (2019)
- Publication Year :
- 2019
- Publisher :
- Korean Society of Obstetrics and Gynecology, 2019.
-
Abstract
- The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Details
- Language :
- English, Korean
- ISSN :
- 22878572 and 22878580
- Volume :
- 62
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- Obstetrics & Gynecology Science
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.01f53643301940f380e192ab2a5a8e80
- Document Type :
- article
- Full Text :
- https://doi.org/10.5468/ogs.2019.62.4.285